Lantern Pharma Inc (LTRN)

Lantern Pharma Inc. is a biotechnology company focused on oncology drug discovery and development, with its common stock listed on NASDAQ under the ticker LTRN. The company’s pipeline includes LP-300, a phase 2 candidate being studied in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, a phase 1 candidate being evaluated across several solid tumors, including pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system cancers; and LP-284, a phase 1 candidate in development for non-Hodgkin’s lymphomas such as mantle cell lymphoma and double hit lymphoma. Lantern Pharma is also advancing STAR-001 in preclinical development for glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and select rare pediatric CNS cancers. In addition, it has an ADC program and collaborations with Oregon Therapeutics, TTC Oncology, and Actuate Therapeutics to support selected oncology programs.

Jump directly to the stock analysis sections supported by the latest available data.